Given that impaired olfactory identification is associated with neurodegenerative diseases such as AD, coupled with the existing knowledge that disease-associated pathological hallmarks (amyloid-beta, tau) in the olfactory bulb of AD patients correlate with the severity of AD [[30], [31], [32]], we believe our cell model fits this purpose. Here, MAPT is linked to Alzheimer disease.